The West African Ebola outbreak has halted progress in tackling HIV in Sierra Leone, shutting health clinics and scaring patients from being tested or seeking treatment. The United Nations Development Programme (UNDP) has raised concerns that HIV prevalence and drug resistance in the country could increase as a result.
02 March 2015 | Reuters
The European AIDS Treatment Group (EATG), Europe’s network of HIV activists, and AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV LGBT civil society organisations and concerned actors, issued an urgent HIV Prevention Manifesto today. We demand that pre-exposure prophylaxis for HIV (PrEP) is made available as soon as possible within the European Union, and that Gilead, the company that makes the PrEP medicine Truvada®, submits an application to the European Medicines Agency (EMA) for a change of indication so that its use to prevent HIV can be approved.
25 February 2015 | EATG
The scientific evidence is clear. As a result of extraordinary advances in biomedical research, we now have the tools we need to end the HIV epidemic in the United States. Or do we? According to, "When We Know Better, We Do Better: State of HIV/AIDS Science and Treatment Literacy," a recently released national report by the Black AIDS Institute and others, the missing link to ending the AIDS epidemic in the U.S. is increasing the science and treatment literacy among the non-medical HIV/AIDS workforce.
04 February 2015 | News Medical
Today my HIV comes of age. 18 years ago I was diagnosed HIV positive. If my HIV was a person it could now vote.
03 February 2015 | Speaking Up! (blog)
We, the undersigned, are organizations of people living with hepatitis C virus (HCV), HIV, and our allies. We believe in equitable access to life-saving treatment for all who need it. We write to express our indignation over Gilead’s pricing and licensing policies for the HCV drug, sofosbuvir.
30 January 2015 | Petitionbuzz
The European AIDS Treatment Group and AVAC organized an unprecedented three-day workshop: New Developments in HIV Prevention. See http://eatgavacprevention.tumblr.com for more. In addition to comprehensive updates on product pipelines across the prevention research landscape, the group discussed the anticipation of the first data from European oral PrEP trials and the implications for PrEP access in Europe.
28 January 2015 | AVAC
New intellectual property ‘think tank’ draft policy already showing alarming trend.
23 January 2015 | Medecins Sans Frontieres press release
Europe is to become the next battleground between Gilead Sciences and AbbVie in their scramble to win share of the fast-growing market for hepatitis C drugs. The companies have been fighting a high-profile price war in the US over a new generation of blockbuster medicines that can cure most people with the virus within weeks. The pair are preparing to open a new front across the Atlantic after European regulators gave AbbVie’s hepatitis C treatment the green light on Friday.
20 January 2015 | Financial Times (free registration required)
The Zimbabwean government has finally dropped stavudine, lamivudine and nevirapine as its first-line HIV therapy in favour of a single dose treatment which has a combination of three drugs, namely tenofovir/lamivudine/efavirenz (TLN).The Government dropped the first line HIV treatment after realizing that it was causing severe side effects on patients. Stanley Takaona of the Zimbabwe HIV and AIDS Activist Union Community Trust said the introduction of the new HIV drug was going to save more lives.
19 January 2015 | AllAfrica
The latest issue of the Global Fund News Flash discusses the importance of dialogue and cooperation for achieving global health goals; reaching key populations with HIV prevention, treatment, and care services; and preventing malaria in Myanmar.
19 January 2015 | The Global Fund